Recombinant Single-chain Factor VIII (rVIII-SingleChain) in Chinese Participants With Hemophilia A Previously Treated With FVIII Products

Who May Qualify: - • Male Chinese participants \<= 65 years of age. - • Participants with severe hemophilia A (FVIII activity \< 1%). - • Participants who have received FVIII products for \>= 150 EDs (\>= 6 years of age) or \>= 50 EDs (\< 6 years of age). Who Should NOT Join This Trial: - • Known hypersensitivity (allergic reaction or anaphylaxis) to any FVIII product or hamster protein. - • Known congenital or acquired coagulation disorder other than congenital FVIII deficiency. - • Currently receiving intravenous (IV) immunomodulating agents such as immunoglobulin or chronic systemic corticosteroid treatment. - • Receiving any cryoprecipitate, whole blood, or plasma within 30 days before administration of rVIII-SingleChain. - • Use of traditional or herbal Chinese medicine(s) with an impact on hemophilia, including coagulation, within 28 days before Day 1 and / or refusal to abstain from these during the study until the end of the participant's participation in the study. Always talk to your doctor about whether this trial is right for you.